6533b874fe1ef96bd12d630a
RESEARCH PRODUCT
Investigation and management of residual sleepiness in CPAP-treated patients with obstructive sleep apnoea: the European view
Sonya CraigJean-louis PépinWinfried RanderathChristian CausséJohan VerbraeckenJerryll AsinFerran BarbéMaria R. Bonsignoresubject
Pulmonary and Respiratory MedicineSleep Apnea ObstructiveSleepinessReproducibility of ResultsSíndromes d'apnea del sonDisorders of Excessive SomnolenceSettore MED/10 - Malattie Dell'Apparato RespiratorioEpworth Sleepiness ScaleObstructive sleep apnea[SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tractmaintenance of wakefulness testHumanswake promoting agents[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieHuman medicineWakefulnessSon--Pacientsdescription
International audience; Excessive daytime sleepiness (EDS) is a major symptom of obstructive sleep apnoea (OSA), defined as the inability to stay awake during the day. Its clinical descriptors remain elusive, and the pathogenesis is complex, with disorders such as insufficient sleep and depression commonly associated. Subjective EDS can be evaluated using the Epworth Sleepiness Scale, in which the patient reports the probability of dozing in certain situations; however, its reliability has been challenged. Objective tests such as the multiple sleep latency test or the maintenance of wakefulness test are not commonly used in patients with OSA, since they require nocturnal polysomnography, daytime testing and are expensive. Drugs for EDS are available in the United States but were discontinued in Europe some time ago. For European respiratory physicians, treatment of EDS with medication is new and they may lack experience in pharmacological treatment of EDS, while novel wake-promoting drugs have been recently developed and approved for clinical use in OSA patients in the USA and Europe. This review will discuss 1) the potential prognostic significance of EDS in OSA patients at diagnosis, 2) the prevalence and predictors of residual EDS in treated OSA patients, and 3) the evolution of therapy for EDS specifically for Europe.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2022-01-01 | European Respiratory Review |